253 related articles for article (PubMed ID: 29247244)
1. Proteasome stress sensitizes malignant pleural mesothelioma cells to bortezomib-induced apoptosis.
Cerruti F; Jocollè G; Salio C; Oliva L; Paglietti L; Alessandria B; Mioletti S; Donati G; Numico G; Cenci S; Cascio P
Sci Rep; 2017 Dec; 7(1):17626. PubMed ID: 29247244
[TBL] [Abstract][Full Text] [Related]
2. Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma.
Gordon GJ; Mani M; Maulik G; Mukhopadhyay L; Yeap BY; Kindler HL; Salgia R; Sugarbaker DJ; Bueno R
Cancer Chemother Pharmacol; 2008 Apr; 61(4):549-58. PubMed ID: 17522864
[TBL] [Abstract][Full Text] [Related]
3. TRAIL and proteasome inhibitors combination induces a robust apoptosis in human malignant pleural mesothelioma cells through Mcl-1 and Akt protein cleavages.
Yuan BZ; Chapman J; Ding M; Wang J; Jiang B; Rojanasakul Y; Reynolds SH
BMC Cancer; 2013 Mar; 13():140. PubMed ID: 23517112
[TBL] [Abstract][Full Text] [Related]
4. Increased sensitivity to apoptosis upon endoplasmic reticulum stress-induced activation of the unfolded protein response in chemotherapy-resistant malignant pleural mesothelioma.
Xu D; Liang SQ; Yang H; Lüthi U; Riether C; Berezowska S; Marti TM; Hall SRR; Bruggmann R; Kocher GJ; Schmid RA; Peng RW
Br J Cancer; 2018 Jul; 119(1):65-75. PubMed ID: 29921948
[TBL] [Abstract][Full Text] [Related]
5. Targeted proteasome inhibition by Velcade induces apoptosis in human mesothelioma and breast cancer cell lines.
Wang Y; Rishi AK; Puliyappadamba VT; Sharma S; Yang H; Tarca A; Dou QP; Lonardo F; Ruckdeschel JC; Pass HI; Wali A
Cancer Chemother Pharmacol; 2010 Aug; 66(3):455-66. PubMed ID: 19960346
[TBL] [Abstract][Full Text] [Related]
6. Loss of C/EBP-β LIP drives cisplatin resistance in malignant pleural mesothelioma.
Kopecka J; Salaroglio IC; Righi L; Libener R; Orecchia S; Grosso F; Milosevic V; Ananthanarayanan P; Ricci L; Capelletto E; Pradotto M; Napoli F; Di Maio M; Novello S; Rubinstein M; Scagliotti GV; Riganti C
Lung Cancer; 2018 Jun; 120():34-45. PubMed ID: 29748013
[TBL] [Abstract][Full Text] [Related]
7. JQ1, a BET Inhibitor, Synergizes with Cisplatin and Induces Apoptosis in Highly Chemoresistant Malignant Pleural Mesothelioma Cells.
Zanellato I; Colangelo D; Osella D
Curr Cancer Drug Targets; 2018; 18(8):816-828. PubMed ID: 28669341
[TBL] [Abstract][Full Text] [Related]
8. Bortezomib-mediated downregulation of S-phase kinase protein-2 (SKP2) causes apoptotic cell death in chronic myelogenous leukemia cells.
Iskandarani A; Bhat AA; Siveen KS; Prabhu KS; Kuttikrishnan S; Khan MA; Krishnankutty R; Kulinski M; Nasr RR; Mohammad RM; Uddin S
J Transl Med; 2016 Mar; 14():69. PubMed ID: 26956626
[TBL] [Abstract][Full Text] [Related]
9. Withaferin A inhibits the proteasome activity in mesothelioma in vitro and in vivo.
Yang H; Wang Y; Cheryan VT; Wu W; Cui CQ; Polin LA; Pass HI; Dou QP; Rishi AK; Wali A
PLoS One; 2012; 7(8):e41214. PubMed ID: 22912669
[TBL] [Abstract][Full Text] [Related]
10. Bortezomib sensitivity is tissue dependent and high expression of the 20S proteasome precludes good response in malignant pleural mesothelioma.
Walter RFH; Sydow SR; Berg E; Kollmeier J; Christoph DC; Christoph S; Eberhardt WEE; Mairinger T; Wohlschlaeger J; Schmid KW; Mairinger FD
Cancer Manag Res; 2019; 11():8711-8720. PubMed ID: 31576173
[TBL] [Abstract][Full Text] [Related]
11. Antagonists of growth hormone-releasing hormone (GHRH) inhibit the growth of human malignant pleural mesothelioma.
Villanova T; Gesmundo I; Audrito V; Vitale N; Silvagno F; Musuraca C; Righi L; Libener R; Riganti C; Bironzo P; Deaglio S; Papotti M; Cai R; Sha W; Ghigo E; Schally AV; Granata R
Proc Natl Acad Sci U S A; 2019 Feb; 116(6):2226-2231. PubMed ID: 30659154
[TBL] [Abstract][Full Text] [Related]
12. Trabectedin Is Active against Malignant Pleural Mesothelioma Cell and Xenograft Models and Synergizes with Chemotherapy and Bcl-2 Inhibition In Vitro.
Hoda MA; Pirker C; Dong Y; Schelch K; Heffeter P; Kryeziu K; van Schoonhoven S; Klikovits T; Laszlo V; Rozsas A; Ozsvar J; Klepetko W; Döme B; Grusch M; Hegedüs B; Berger W
Mol Cancer Ther; 2016 Oct; 15(10):2357-2369. PubMed ID: 27512118
[TBL] [Abstract][Full Text] [Related]
13. Novel proteasome inhibitors to overcome bortezomib resistance.
Ruschak AM; Slassi M; Kay LE; Schimmer AD
J Natl Cancer Inst; 2011 Jul; 103(13):1007-17. PubMed ID: 21606441
[TBL] [Abstract][Full Text] [Related]
14. BAK and NOXA are critical determinants of mitochondrial apoptosis induced by bortezomib in mesothelioma.
Busacca S; Chacko AD; Klabatsa A; Arthur K; Sheaff M; Barbone D; Mutti L; Gunasekharan VK; Gorski JJ; El-Tanani M; Broaddus VC; Gaudino G; Fennell DA
PLoS One; 2013; 8(6):e65489. PubMed ID: 23762382
[TBL] [Abstract][Full Text] [Related]
15. Apigenin manipulates the ubiquitin-proteasome system to rescue estrogen receptor-β from degradation and induce apoptosis in prostate cancer cells.
Singh V; Sharma V; Verma V; Pandey D; Yadav SK; Maikhuri JP; Gupta G
Eur J Nutr; 2015 Dec; 54(8):1255-67. PubMed ID: 25408199
[TBL] [Abstract][Full Text] [Related]
16. PI3 Kinase Pathway and MET Inhibition is Efficacious in Malignant Pleural Mesothelioma.
Kanteti R; Riehm JJ; Dhanasingh I; Lennon FE; Mirzapoiazova T; Mambetsariev B; Kindler HL; Salgia R
Sci Rep; 2016 Sep; 6():32992. PubMed ID: 27623107
[TBL] [Abstract][Full Text] [Related]
17. Proteasome Inhibitors Bortezomib and Carfilzomib Stimulate the Transport Activity of Human Organic Anion Transporter 1.
Fan Y; You G
Mol Pharmacol; 2020 Jun; 97(6):384-391. PubMed ID: 32234809
[TBL] [Abstract][Full Text] [Related]
18. Exocytosis of polyubiquitinated proteins in bortezomib-resistant leukemia cells: a role for MARCKS in acquired resistance to proteasome inhibitors.
Franke NE; Kaspers GL; Assaraf YG; van Meerloo J; Niewerth D; Kessler FL; Poddighe PJ; Kole J; Smeets SJ; Ylstra B; Bi C; Chng WJ; Horton TM; Menezes RX; Musters RJ; Zweegman S; Jansen G; Cloos J
Oncotarget; 2016 Nov; 7(46):74779-74796. PubMed ID: 27542283
[TBL] [Abstract][Full Text] [Related]
19. Combination of Second-Generation Proteasome Inhibitor Carfilzomib with Bortezomib in Four Different Breast Cancer Cell Lines.
Altundag EM; Yilmaz AM; Sahin A; Yilmaz BK
Anticancer Agents Med Chem; 2022 Aug; 22(16):2909-2918. PubMed ID: 35352669
[TBL] [Abstract][Full Text] [Related]
20. Ubiquitin-proteasome system stress sensitizes ovarian cancer to proteasome inhibitor-induced apoptosis.
Bazzaro M; Lee MK; Zoso A; Stirling WL; Santillan A; Shih IeM; Roden RB
Cancer Res; 2006 Apr; 66(7):3754-63. PubMed ID: 16585202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]